The global generic sterile injectables market is in trends by rising demand for affordable medications. Generic sterile injectables are non-biological and off-patent products administered parenterally for acute care. These injectables deliver therapeutic benefits for diseases including cancer, respiratory infections, cardiovascular diseases. The affordability and effectiveness of generic injectables helps patients adhere to treatments.
The Global generic sterile injectables market is estimated to be valued at US$ 38,706.5 Mn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the generic sterile injectables market are Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy’s Laboratory, Mylan N.V., Sun Pharmaceutical Industries Ltd. Growing demand for affordable treatment options and rise in chronic diseases are fueling market growth. The availability of generic sterile injectables at lower costs compared to branded therapies is increasing their adoption.
Key players are focusing on expanding their product portfolio and global footprint to capitalize on the market potential. The large patient pool suffering from chronic conditions worldwide offers opportunities for market leaders to strengthen distribution networks internationally.
Market key trends
The increasing incidence of chronic diseases worldwide is driving the demand for injectable generics. Globally 1 in 4 individuals suffer from cardiovascular diseases, diabetes or cancer. As geriatric population prone to multiple conditions expands, the need for cost-effective injections rises. This trend will continue fuelling the $38 billion generic sterile injectables market over the forecast period.
Porter's Analysis
Threat of new entrants: High capital requirements for manufacturing facilities and regulatory approvals pose barriers for new players. Bargaining power of buyers: Large group purchasing organizations and new generic entries creates pricing pressure on established players. Bargaining power of suppliers: Few raw material suppliers gives them pricing leverage. Threat of new substitutes: Strong presence of patented drugs limits threat. Competitive rivalry: Intense competition among well-established players to gain market share through acquisitions, new launches and strategic collaborations.
North America holds the largest share of the generic sterile injectables market, owing to the high adoption of generics and the increased incidence of chronic diseases. Asia Pacific is expected to grow at the highest CAGR during the forecast period due to improving healthcare infrastructure, rising medical tourism, and presence of contract manufacturing hubs in India and China.
Germany accounts for the largest share of the European generic sterile injectables market. This can be attributed to favorable reimbursement policies by government & private bodies, strong economy, and large healthcare expenditure. Emerging markets such as China, India, Brazil are projected to offer high growth opportunities for players to leverage and establish low-cost manufacturing and sales networks.
No comments:
Post a Comment